Patient’s values and preferences for stroke prevention in atrial fibrillation: balancing stroke and bleeding risk with oral anticoagulation

Deirdre A. Lane; Gregory Y. H. Lip

doi:10.1160/TH14-01-0063

Thrombosis and Haemostasis, Inhaltsverzeichnis

Thromb Haemost 2014; 111(03): 381-383
DOI: 10.1160/TH14-01-0063

Editorial Focus

Schattauer GmbH

Patient’s values and preferences for stroke prevention in atrial fibrillation: balancing stroke and bleeding risk with oral anticoagulation

Deirdre A. Lane

¹University of Birmingham Centre for Cardiovascular Sciences, City Hospital, Birmingham, UK

,

Gregory Y. H. Lip

¹University of Birmingham Centre for Cardiovascular Sciences, City Hospital, Birmingham, UK

› Institutsangaben

Abstract

Note: The review process for this editorial was handled by Christian Weber, Editor in Chief.

Volltext

Referenzen

References
1 Camm AJ, Lip GY, De Caterina R. et al. ESC Committee for Practice Guidelines-CPG; Document Reviewers.. 2012 focused update of the ESC Guidelines for the management of atrial fibrillation: an update of the 2010 ESC Guidelines for the management of atrial fibrillation--developed with the special contribution of the European Heart Rhythm Association.. Europace 2012; 14: 1385-1413.
2 LaHaye S, Regpala S, Lacombe S. et al. Evaluation of patients’ attitudes towards stroke prevention and bleeding risk in atrial fibrillation.. Thromb Haemost 2014; 111: 465-473.
3 Devereaux PJ, Anderson DR, Gardner MJ. et al. Differences between perspectives of physicians and patients on anticoagulation in patients with atrial fibrillation: observational study.. Br Med J 2001; 323: 1218-1222.
4 Alonso-Coello P, Montori VM, Solà I. et al. Values and preferences in oral anticoagulation in patients with atrial fibrillation, physicians’ and patients’ perspectives: protocol for a two-phase study.. BMC Health Serv Res 2008; 8: 221.
5 Man-Son-Hing M, Laupacis A, O’ Connor AM. et al. Patient preference-based treatment thresholds and recommendations: a comparison of decision-analytic modeling with the probability-tradeoff technique.. Med Decis Making 2000; 20: 394-403.
6 MacLean S, Mulla S, Akl EA. et al. Patient values and preferences in decision making for antithrom-botic therapy: a systematic review.. Chest 2012; 141: e1S-e23S.
7 Edwards A, Elwyn G, Mulley A. Explaining risks: turning numerical data into meaningful pictures.. Br Med J 2002; 324: 827-830.
8 Lane DA, Barker RV, Lip GYH. Best practice for atrial fibrillation patient education.. Curr Pharm Des; 2014. in press.
9 Pugh D, Mead GE. Attitudes of physicians regarding anticoagulationfor atrial fibrillation: a systematic review.. Age Ageing 2011; 40: 675-683.
10 Lane DA, Ponsford J, Shelley A. et al. Patient knowledge and perceptions of atrial fibrillation and anticoagulant therapy: effects of an educational intervention programme.. The West Birmingham Atrial Fibrillation Project. Int J Cardiol 2006; 110: 354-358.
11 Lip GYH, Agnelli G, Thach AA. et al. Oral anticoagulation in atrial fibrillation: A pan-European patient survey.. Eur J Intern Med 2007; 18: 202-208.
12 Coehlo-Dantas G, Thompson BV, Manson JA. et al. Patients’ perspectives on taking warfarin: qualitative study in family practice.. BMC Fam Pract 2004; 5: 15.
13 Lip GYH, Kamath S, Jafri M. et al. Ethnic differences in patient perceptions of atrial fibrillation and anticoagulation therapy: the West Birmingham Atrial Fibrillation Project.. Stroke 2002; 33: 238-244.
14 Clarkesmith DE, Pattison HM, Lip GYH. et al. Educational intervention improves anticoagulation control in atrial fibrillation patients: the TREAT study.. PLOS ONE 2013; 8: e74037.
15 Gallego P, Roldan V, Marín F. et al. Cessation of oral anticoagulation in relation to mortality and the risk of thrombotic events in patients with atrial fibrillation.. Thromb Haemost 2013; 110: 1189-1198.
16 De Caterina R, Husted S, Wallentin L. et al. European Society of Cardiology Working Group on Thrombosis Task Force on Anticoagulants in Heart Disease.. Vitamin K antagonists in heart disease: current status and perspectives (Section III).. Position paper of the ESC Working Group on Thrombosis--Task Force on Anticoagulants in Heart Disease. Thromb Haemost 2013; 110: 1087-1107.
17 De Caterina R, Husted S, Wallentin L. et al. European Society of Cardiology Working Group on Thrombosis Task Force on Anticoagulants in Heart Disease.. General mechanisms of coagulation and targets of anticoagulants (Section I).. Position Paper of the ESC Working Group on Thrombosis--Task Force on Anticoagulants in Heart Disease. Thromb Haemost 2013; 109: 569-579.
18 Banerjee A, Lane DA, Torp-Pedersen C. et al. Net clinical benefit of new oral anticoagulants (dabigatran, rivaroxaban, apixaban) versus no treatment in a ‘real world’ atrial fibrillation population: a modelling analysis based on a nationwide cohort study.. Thromb Haemost 2012; 107: 584-589.
19 Huisman MV, Lip GY, Diener HC. et al. Dabigatran etexilate for stroke prevention in patients with atrial fibrillation: resolving uncertainties in routine practice.. Thromb Haemost 2012; 107: 838-847.
20 Turpie AG, Kreutz R, Llau J. et al. Management consensus guidance for the use of rivaroxaban--an oral, direct factor Xa inhibitor.. Thromb Haemost 2012; 108: 876-886.